PEOPLE ON THE MOVE
Viventia Bio
Oncology drug company Viventia Bio has appointed Erick Lucera (pictured) as Chief Financial Officer and Gregory Adams to the new position of Chief Product Development Officer.
Lucera will be responsible for all financial planning and reporting and will head investor relations and external communications. He has two decades’ experience in the life sciences,
including 15 on the buy side as a portfolio manager and analyst following the healthcare sector. He has also served as VP, Corporate Development at Aratana Therapeutics and as Vice President and Healthcare Analyst at Eaton Vance Investment Managers.
Gregory Adams, an immunologist, will lead the company’s pipeline of oncology antibody drug conjugates (ADCs).
Adams was CEO of computational antibody design company RAbD Biotech LLC, where he helped develop ovarian cancer agent RAD-003. He has also worked as the Director of Biological Research and Therapeutics at Fox Chase Cancer Center and sat on the Scientific Advisory Board of Viventia for 12 years.
Viventia is expected to bring its lead candidates, Vicinium for bladder cancer and Proxinium for head and neck cancer, to Phase III trials this year.
